News

Podcast

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Author(s):

Alexandra Gerlach, Associate Editor

Pharmacists discuss how drug design impacts drug efficacy and indications for HER2-low and -ultra-low breast cancer.

Related Videos
5 experts in this video
5 experts in this video
Image credit: Photo18@desing | stock.dobe.com
Image credit: Jack Fotografo | stock.adobe.com
Related Content
Woman measuring glucose levels | Image Credit: © fizkes - stock.adobe.com
April 29th 2025

Hyperglycemia in HR+ Breast Cancer: Prevention and Management Strategies for Oncology Pharmacists

Alexandra Gerlach, Associate Editor
The RIVAWAR Trial and ACS Guidelines for LV Thrombus
April 22nd 2025

The RIVAWAR Trial and ACS Guidelines for LV Thrombus

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP Aislinn Antrim, Managing Editor
FDA Approves Prademagene Zamikeracel, First and Only Cell-Based Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
April 29th 2025

FDA Approves Prademagene Zamikeracel, First and Only Cell-Based Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Aislinn Antrim, Managing Editor
Antibody Drug Conjugates and Breast Cancer: Insights from a Pharmacy Times Peer Exchange
April 14th 2025

Antibody Drug Conjugates and Breast Cancer: Insights from a Pharmacy Times Peer Exchange

Alexandra Gerlach, Associate Editor
Illustrative graphic showing racially diverse group of women with breast cancer | Image Credit: © ST.art - stock.adobe.com
April 29th 2025

Breast Cancer Mortality Declines in Younger Women, But Survival Gaps Remain

Alexandra Gerlach, Associate Editor
Applying topical cream to irritated skin | Image Credit: @ chatuphot - stock.adobe.com
April 28th 2025

Investigational LUT014 Gel Improves Acneiform Rash in Patients With Metastatic Colorectal Cancer

Alexandra Gerlach, Associate Editor